The use of zanamivir in seven patients with influenza (three A and four B) post allograft is described. Inhaled zanamivir (10 mg twice daily) was continued from the diagnosis of influenza until excretion of virus ceased (median duration 15 days, range 5 to 44 days). There was no toxicity attributable to zanamivir and rapid resolution of influenza symptoms was seen. There was no mortality due to influenza in the seven patients. The good outcome of 30 previous patients with influenza post transplant is described. A randomised multicentre study would be required to demonstrate efficacy.
Community respiratory viral infections are an important cause of morbidity and mortality after allogeneic SCT, particularly those using alternative donors. 1, 2 Previously the only therapy available for influenza post SCT was amantadine; the efficacy of this is uncertain and it can only be used for influenza A.
We report the administration of the neuraminidase inhibitor, zanamivir, to seven patients post allogeneic stem cell transplantation, all of which took place during the winter. In immunocompetent patients, zanamivir has been shown to decrease duration of viral excretion [3] [4] [5] and to have a most acceptable toxicity profile. However, its use has not previously been documented in the bone marrow transplant setting.
Patients, methods and results
Clinical characteristics of the seven patients are shown in Table 1 . Although there is no proven therapy for many of the respiratory viruses, it has been the policy of our BMT Three patients were adolescents and four were adults. Three grafts were from alternative donors and these grafts were T cell-depleted. The median time to diagnosis was just under 4 weeks post BMT (Table 2) : four patients had engrafted at the time of viral diagnosis. One patient who acquired influenza 2. years post transplant had associated pre-existing severe pulmonary compromise due to bronchiolitis obliterans. All patients had secretions analysed within 24 h of the respiratory symptoms developing and virus diagnosis occurred within 24 h of the sample being collected. Three had influenza A and four influenza B. All patients had classical symptoms of influenza (fever, headache, myalgia and rhinorrhoea), but four were more unwell with dyspnoea and had significant oxygen desaturation. Four patients were considered to have evidence of viral pneumonitis and in particular one patient (aged 40) had an oxygen saturation of 85%, a respiratory rate of Ͼ30 per min and marked radiological changes at presentation. However, it should be pointed out that three of the seven patients were being treated with liposomal amphotericin for suspected fungal infection. The most common site of virus diagnosis was the sputum, but nasopharyngeal aspirates were also an important diagnostic specimen. Inhaled zanamivir (10 mg twice daily) was commenced on microbiological confirmation of influenza virus infection with the DIF test, usually with a turnaround time of less than 6 h. Because of the known prolonged excretion of virus in BMT patients and in spite of the possibility of inducing antiviral drug resistance, it was decided that zanamivir should be continued until it was documented that virus excretion had ceased, with the median duration of use being 15 days (range 5-44 days). Patients were analysed weekly until no virus was detectable in secretions or the secretions had ceased. One patient received additional amantidine (100 mg/day for 14 days); there was no attributable toxicity. There was no toxicity attributable to zanamivir; symptomatic bronchospasm was not seen. Most patients had rapid resolution of influenza symptoms and the classical complications of influenza infection (sinusitis, purulent bronchitis, otitis media) were not seen in any of the patients. Re-analysis of respiratory secretions was performed at least at weekly intervals: the median duration of virus excretion was 15 days (range 4-37). Six of seven patients are alive more than 3 months from the diagnosis of influenza; there were no deaths attributable to influenza. The sole death occurred in a patient with early disease recurrence post transplant.
We then reviewed the case notes of all allogeneic transplant patients diagnosed with influenza (in the immediate pre-or post transplant period) in our unit (which specialises in alternative donor SCT) over a 7-year period. Thirty cases of influenza (24 A and six B) have occurred since 1993 in 509 allografts (incidence 6%). Of these 30 cases, 20 received stem cells from unrelated donors, two from haploidentical sibling donors, and the remainder from sibling donors. Median patient age was 17 (range 2-49) years. The median time post BMT to virus diagnosis was 29 days (range −12 to 1500). Ten had radiological changes felt to be due to influenza and 11 had oxygen desaturation to 95% or less. Seven of the 30 patients have died, but no deaths were directly attributable to influenza. Three patients experienced graft failure occurring after the infection, but all of these survived.
Discussion
Respiratory virus infection is an important cause of morbidity and mortality post stem cell transplantation, particularly when alternative donors are used. 2, 6 Few of these viruses have proven therapies in the transplant setting. Serious morbidity can occur through viral pneumonitis, virusassociated myelosuppression and graft failure, and possibly by triggering GVHD. However, the natural history of viral infections post SCT is highly variable making it difficult to decide who should be treated and who just observed. 6 Influenza is a less commonly documented viral respiratory pathogen but the attributable mortality is high in some series, 7 although not in the experience of our unit. Excretion of viruses may be prolonged post allograft and it is uncertain how long to continue antiviral therapy. Many of our patients were unwell at the time of viral diagnosis and some had not engrafted. For this reason and because zanamavir had few attributable side-effects in our patients, 8 we decided to continue therapy until symptoms had subsided and virus was no longer demonstrable. A theoretical objection to this would be antivirus resistance. 9 None of our patients died due to influenza infection, but it is not possible to state whether our therapy was effective. However, it is of interest that four of these patients had evidence of lower tract infection (one severe), yet all of them survived. The low incidence of toxicity seen in our patients means that a randomised placebo controlled trial would be feasible; only a large multicentre study would be able to demonstrate efficacy convincingly. This study should possibly be confined to patients with lower tract involvement. Whether adding amantadine to zanamavir confers any additional benefit to patients with influenza A also requires further examination, as does the possible role of ribavirin.
